Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops pantoprazole magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the purgenesis name. Devonian Health Group Inc. was founded in 2017 and is headquartered in Québec, Canada.
Frequently asked questions
What sector does Devonian Health Group Inc (GSD) operate in?
Devonian Health Group Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Devonian Health Group Inc (GSD) current stock price?
As of the latest data, Devonian Health Group Inc stock price is CA$7.75, with a previous close of CA$7.75.
What is Devonian Health Group Inc (GSD) current market capitalization?
Devonian Health Group Inc market cap is approximately 21.55 million.
What is Devonian Health Group Inc (GSD) Earnings Per Share (EPS)?
The trailing EPS is -CA$2.25.
Does Devonian Health Group Inc (GSD) pay dividends?
No. Devonian Health Group Inc does not pay a dividend.
When is Devonian Health Group Inc (GSD) next earnings report?
Devonian Health Group Inc is expected to release its next earnings report on October 31, 2026.
What is Devonian Health Group Inc (GSD) beta (volatility) score?
Devonian Health Group Inc has a beta of 1.279, suggesting it is more volatile than the market.
